Life
STAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more
Infrastructure lens: A small biotech was forced to being winding down its operations after the FDA abruptly postponed a key meeting for four months
Editorial Staff
1 min read
Summary
- Primary development: STAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more
- Coverage synthesized from 1 sources in the cluster.
- This draft should be editor-reviewed before publication.
Key Facts
| Fact | Value |
|---|---|
| Primary source | STAT |
| Source count | 1 |
| First published | 2026-04-06T13:51:28.000Z |